Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
ABEO
Abeona Therapeutics
$6.24
Chart
$4.92 (+26.83%)
$5.16 (+20.93%)
$5.25 (+18.86%)
$4.57 (+36.54%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
ABEO
Abeona Therapeutics
Current Price
$6.24
Login to view Abeona Therapeutics (ABEO) recommendation from the last 90 days from financial news and social media.
Chart
$4.92 (+26.83%)
$5.16 (+20.93%)
$5.25 (+18.86%)
$4.57 (+36.54%)
ABEO Latest Headlines
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference. ) today announced that Vish Seshadri Ph.D. Chief Executive Officer and Madhav Vasanthavada Ph.D. Chief Commercial Officer will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday June 4 2025 at 11:40 a.m. Eastern Time.. The webcast will be archived for 30 days.Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious di
Today
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference. ) today announced that Vish Seshadri Ph.D. Chief Executive Officer and Madhav Vasanthavada Ph.D. Chief Commercial Officer will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday June 4 2025 at 11:40 a.m. Eastern Time.. The webcast will be archived for 30 days.Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious di
Today
Abeona Therapeutics ® to Present at the Jefferies Global Healthcare Conference.
Today
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference.
Today
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis osa Market | DelveInsight. Approximately a year after the FDA rejected its previous approval submission Abeona announced that the agency had approved ZEVASKYN its autologous cell-based gene therapy for both adult and pediatric patients with RDEB. This approval marks Abeonas entry into the commercial gene therapy...
Thu May 22, 2025
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis osa Market | DelveInsight. Approximately a year after the FDA rejected its previous approval submission Abeona announced that the agency had approved ZEVASKYN its autologous cell-based gene therapy for both adult and pediatric patients with RDEB. This approval marks Abeonas entry into the commercial gene therapy...
Thu May 22, 2025
ABEO: Sells Priority Review Voucher for $155 Million. By Business UpdateFirst Qualified Treatment Center ActivatedOn May 14 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Childrens Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and the first patient is likely to be biopsied in July and treated in August.Lurie Childrens is one of the largest North Ameri
Mon May 19, 2025
ABEO: Sells Priority Review Voucher for $155 Million. By Business UpdateFirst Qualified Treatment Center ActivatedOn May 14 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Childrens Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and the first patient is likely to be biopsied in July and treated in August.Lurie Childrens is one of the largest North Ameri
Mon May 19, 2025
ABEO: Sells Priority Review Voucher for $155 Million. By Business UpdateFirst Qualified Treatment Center ActivatedOn May 14 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Childrens Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and the first patient is likely to be biopsied in July and treated in August.Lurie Childrens is one of the largest North Ameri
Mon May 19, 2025
ABEO: Sells Priority Review Voucher for $155 Million. By Business UpdateFirst Qualified Treatment Center ActivatedOn May 14 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the Ann & Robert H. Lurie Childrens Hospital of Chicago has been activated as the first Qualified Treatment Center (QTC) for Zevaskyn™. The hospital has completed all QTC start-up activities and the first patient is likely to be biopsied in July and treated in August.Lurie Childrens is one of the largest North Ameri
Mon May 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABEO Stock trends
ABEO Stock performance
ABEO Stock analysis
ABEO investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
